CFM
RAPT

Catalyst Funds Management’s RAPT Therapeutics RAPT Stock Holding History

Catalyst Funds Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-550
Closed -$39.5K – 1516
2024
Q1 		$39.5K Buy
+550
New +$76.5K 0.01% 621

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Catalyst Funds Management's RAPT Position: Q2 2024 in Review

Catalyst Funds Management sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 550 shares — an estimated $39.5K sold.

Catalyst Funds Management first reported a position in RAPT in Q1 2024 and held it in 1 quarter. The position peaked at $39.5K in Q1 2024. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

  • Catalyst Funds Management reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 550 RAPT Therapeutics shares in Q2 2024, an estimated $39.5K.
  • Catalyst Funds Management first reported a position in RAPT Therapeutics in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's RAPT Therapeutics position peaked at $39.5K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.